A noninvasive multi-analyte diagnostic assay: Combining protein and DNA markers to stratify bladder cancer patients

Open Access Journal of Urology

Volumn 4, Issue 1, 2012, Pages 17-26

  Fernandez, Cecilia A ^a   Millholland, John M ^a   Zwarthoff, Ellen C ^b   Feldman, Adam S ^c   Jeffrey Karnes, R ^d   Shuber, Anthony P ^a  

^a Predictive Biosciences Inc   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d MAYO CLINIC   (United States)

Author keywords

Bladder cancer; Diagnostics; FGFR3; Matrix metalloproteinase

Indexed keywords

BIOLOGICAL MARKER; GELATINASE A; GELATINASE B; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR TWIST1; UNCLASSIFIED DRUG;

ARTICLE; BLADDER CANCER; CANCER PATIENT; CANCER RECURRENCE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DNA DEGRADATION; DNA MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; EXON; FGFR3 GENE; GENE; GENE MUTATION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; NON INVASIVE PROCEDURE; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PROTEIN METHYLATION; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; URINALYSIS;

EID: 84859044555     PISSN: None     EISSN: 11791551     Source Type: Journal    
DOI: 10.2147/RRU.S28959     Document Type: Article

References (27)

1. American Cancer Society: Cancer Facts and Figures. Available from: www.cancer.org. Accessed March 6, 2008.
2. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 2003;21(18):1315-1330.
3. Hong YM, Loughlin KR. Economic impact of tumor markers in bladder cancer surveillance. Urology. 2008;71(1):131-135.
4. Duggan B, Williamson K. Molecular markers for predicting recurrence, progression and outcomes of bladder cancer (do the poster boys need new posters?). Curr Opin Urol. 2004;14(5):277-286.
5. Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol. 1999;43 Suppl:S42-S51.
6. Moses MA. The regulation of neovascularization of matrix metalloproteinases and their inhibitors. Stem Cells. 1997;15(3):180-189.
7. Eissa S, Ali-Labib R, Swellam M, Bassiony M, Tash F, El-Zayat TM. Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine. Eur Urol. 2007;52(5):1388-1396.
8. Fernandez CA, Yan L, Louis G, Yang J, Kutok JL, Moses MA. The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res. 2005;11(15): 5390-5395.
9. Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC, Freeman MR. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res. 1998;58(7):1395-1399.
10. Smith ER, Manfredi M, Scott RM, Black PM, Moses MA. A recurrent craniopharyngioma illustrates the potential usefulness of urinary matrix metalloproteinases as noninvasive biomarkers: case report. Neurosurgery. 2007;60(6):E1148-E1149; discussion E1149.
11. Smith ER, Zurakowski D, Saad A, Scott RM, Moses MA. Urinary biomarkers predict brain tumor presence and response to therapy. Clin Cancer Res. 2008;14(8):2378-2386.
12. Fernandez CA, Wszolek MF, Loughlin KR, Libertino JA, Summerhayes IC, Shuber AP. A novel approach to using matrix metalloproteinases for bladder cancer. J Urol. 2009;182(5):2188-2194.
13. Cappellen D, De Oliveira C, Ricol D, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet. 1999;23(1):18-20.
14. Johnson DE, Williams LT. Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res. 1993;60:1-41.
15. Tomlinson DC, Baldo O, Harnden P, Knowles MA. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol. 2007;213(1):91-98.
16. Billerey C, Chopin D, Aubriot-Lorton MH, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol. 2001;158(6):1955-1959.
17. Junker K, van Oers JM, Zwarthoff EC, Kania I, Schubert J, Hartmann A. Fibroblast growth factor receptor 3 mutations in bladder tumors correlate with low frequency of chromosome alterations. Neoplasia. 2008;10(1):1-7.
18. van Oers JM, Zwarthoff EC, Rehman I, et al. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur Urol. 2009;55(3):650-657.
19. Gort EH, Suijkerbuijk KP, Roothaan SM, et al. Methylation of the TWIST1 promoter, TWIST1 mRNA levels, and immunohistochemical expression of TWIST1 in breast cancer. Cancer Epidemiol Biomarkers Prev. 2008;17(12):3325-3330.
20. Okada T, Suehiro Y, Ueno K, et al. TWIST1 hypermethylation is observed frequently in colorectal tumors and its overexpression is associated with unfavorable outcomes in patients with colorectal cancer. Genes Chromosomes Cancer. 2010;49(5):452-462.
21. Ulazzi L, Sabbioni S, Miotto E, et al. Nidogen 1 and 2 gene promoters are aberrantly methylated in human gastrointestinal cancer. Mol Cancer. 2007;6:17.
22. Xie F, Li K, Ouyang X. Twist, an independent prognostic marker for predicting distant metastasis and survival rates of esophageal squamous cell carcinoma patients. Clin Exp Metastasis. 2009;26(8): 1025-1032.
23. Renard I, Joniau S, van Cleynenbreugel B, et al. Identification and validation of the methylated TWIST1 and NID2 genes through real- time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples. Eur Urol. 2010;58(1):96-104.
24. Petersen M, Wengel J. LNA: a versatile tool for therapeutics and genomics. Trends Biotechnol. 2003;21(2):74-81.
25. Bruge F, Littarru GP, Silvestrini L, Mancuso T, Tiano L. A novel Real Time PCR strategy to detect SOD3 SNP using LNA probes. Mutat Res. 2009;669(1-2):80-84.
26. Orum H, Jakobsen MH, Koch T, Vuust J, Borre MB. Detection of the factor V Leiden mutation by direct allele-specific hybridization of PCR amplicons to photoimmobilized locked nucleic acids. Clin Chem. 1999;45(11):1898-1905.
27. Zuiverloon TC, van der Aa MN, van der Kwast TH, et al. Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer. Clin Cancer Res. 2010;16(11):3011-3018.